Acute dermal toxicity evaluation of eugenol-incorporated hydrogel in Sprague Dawley rats
The Journal of Phytopharmacology · 08.05.2026 · 15 (2) · 192-195
DOI: 10.31254/phyto.2026.15210 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Phytopharmacology, online erschienen am 08.05.2026. Verfasst von Pooja Krishna Kizhekku Veettil und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Multidrug-resistant Staphylococcus aureus (MDRSA) infections significantly impair wound healing, often leading to chronic wounds and systemic complications. There is a need for wound dressings that are not only antibacterial but also biocompatible. Essential oils, such as eugenol, possess potent antibacterial properties, but their direct application is limited by volatility and instability. Incorporating eugenol into a polymeric hydrogel provides a stable delivery system, while ensuring safety prior to in vivo use is essential.
Objectives
This study aimed to evaluate the dermal safety of eugenol-incorporated chitosan-PVA hydrogel (Eug-CH) in Sprague Dawley rats, following OECD Test Guideline 402. Materials and Methods: The inert chitosan-PVA hydrogel was synthesised via chemical crosslinking, followed by incorporation of eugenol as an emulsion. Acute dermal toxicity testing was conducted according to OECD 402, with topical application to the dorsal skin under semi-occlusive conditions. Sequential doses up to 2000 mg/kg were administered, with a total of five female rats used. Animals were monitored intensively for 24 h post-application and daily for 14 days, assessing dermal integrity, behaviour and systemic signs of toxicity.
Results
Topical application of Eug-CH produced no mortality or toxicity at doses up to the tested limit dose of 2000 mg/kg. Observations over 14 days revealed no adverse effects, including erythema, edema, tremors, convulsions, or behavioural abnormalities. Gross necropsy showed no organ abnormalities and a normal increase in body weight was noted. These findings indicate that the Eug-CH formulation is safe for dermal application in rats even upto the limit dose level.
Conclusion
The Eug-CH hydrogel showed no mortality, skin irritation or pathological changes at doses ranging from 200 to 2000 mg/kg, with normal body weight gain observed over 14 days. With an LD₅₀ exceeding 2000 mg/kg, the formulation is classified as GHS Category 5 (low hazard), confirming its safety for regulatory purposes. These results indicate that the eugenol incorporated hydrogel is highly biocompatible and suitable as an antibacterial wound dressing without risk of dermal toxicity.
Zitieren
APA
Veettil, P. K. K., Sasidharan, S. R., Ravindran, N. A., John, P., Rajappan, A., & Varghese, R. (2026). Acute dermal toxicity evaluation of eugenol-incorporated hydrogel in Sprague Dawley rats. The Journal of Phytopharmacology, 15(2), 192-195. https://doi.org/10.31254/phyto.2026.15210
Vancouver
Veettil PKK, Sasidharan SR, Ravindran NA, John P, Rajappan A, Varghese R. Acute dermal toxicity evaluation of eugenol-incorporated hydrogel in Sprague Dawley rats. The Journal of Phytopharmacology. 2026;15(2):192-195. doi:10.31254/phyto.2026.15210
BibTeX
@article{Veettil2026,
author = {Veettil, Pooja Krishna Kizhekku and Sasidharan, Suja Rani and Ravindran, Nisha Ayinikkattil and John, Preethy and Rajappan, Anoopraj and Varghese, Reji},
title = {Acute dermal toxicity evaluation of eugenol-incorporated hydrogel in Sprague Dawley rats},
journal = {The Journal of Phytopharmacology},
year = {2026},
volume = {15},
number = {2},
pages = {192--195},
doi = {10.31254/phyto.2026.15210}
}
EUVIMED